ประเทศ: แคนาดา
ภาษา: อังกฤษ
แหล่งที่มา: Health Canada
LISINOPRIL (LISINOPRIL DIHYDRATE)
COBALT PHARMACEUTICALS COMPANY
C09AA03
LISINOPRIL
5MG
TABLET
LISINOPRIL (LISINOPRIL DIHYDRATE) 5MG
ORAL
30/100/500
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0121550003; AHFS:
CANCELLED PRE MARKET
2017-09-01
______________________________________________________________________________________________ _ _LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _ _Page 1 of 44 _ _ _ _ _ PRODUCT MONOGRAPH PR LISINOPRIL Lisinopril Tablets, USP 5 mg, 10 mg and 20 mg (of Lisinopril as Lisinopril Dihydrate) Angiotensin Converting Enzyme Inhibitor Cobalt Pharmaceuticals Company 6500 Kitimat Road Mississauga, Ontario Canada, L5N 2B8 CONTROL NUMBER: 172480 Date of Revision: March 4, 2014 ______________________________________________________________________________________________ _ _LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _ _Page 2 of 44 _ _ _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 5 WARNINGS AND PRECAUTIONS ......................................................................................... 5 ADVERSE REACTIONS ......................................................................................................... 11 DRUG INTERACTIONS ......................................................................................................... 17 DOSAGE AND ADMINISTRATION ..................................................................................... 20 OVERDOSAGE ....................................................................................................................... 23 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 23 STORAGE AND STABILITY ................................................................................................. 26 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................... อ่านเอกสารฉบับเต็ม